BETRF
BetterLife Pharma Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Apr 13 BetterLife Pharma announced a $500,000 private placement, multiple d…
- R Jun 26 BetterLife Pharma's 6-K filing for the fiscal Q1 ended April 30, 202…
- X Sep 15 Short interest falls 57.3% to 126.7K
- R Sep 30 BetterLife Pharma filed its Q2 FY2027 interim financials (period end…
- X Sep 30 Short interest falls 44.5% to 70.4K
Signal stack
Where each data set points today.
- Short sellersCOVERING
Short interest −44.5% to 70.4K shares. 1.0 days to cover.
- TrendDOWNTREND
21% below its 50-day average.
Earnings setup
EstimatesRevision history: 🔒 Fresh data — subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data — subscribers only | |||
| Next Q | 🔒 Fresh data — subscribers only | |||
| Current FY | 🔒 Fresh data — subscribers only | |||
| Next FY | 🔒 Fresh data — subscribers only | |||
Short side
FINRA· Sep 30, 2026SecBot reports
7 filings · 1 bullish · 0 bearish · 3 mixed · 3 neutral- BULLISH 6-KSep 30, 2026
BetterLife Pharma filed its Q2 FY2027 interim financials (period ended July 31, 2026) alongside a…
The $138.7M raise eliminates near-term going concern risk and funds the entire BETR-001 clinical program through Phase 2. Watch for IND filing in Q1 2027 and resolution of the director's convertible…
- NEUTRAL SC 13GSep 22, 2026
RA Capital Management, L.P. and affiliated entities disclosed a 9.0% passive stake in BetterLife…
RA Capital's 9% stake signals conviction but is filed as passive (13G). Monitor for any future conversion to 13D or additional purchases, which would indicate a shift toward activist intent. The…
- NEUTRAL 6-KSep 15, 2026
BetterLife Pharma filed its Notice of Annual General Meeting and Information Circular for the…
This is a routine proxy filing with no new financial or operational catalysts. The going concern risk is the dominant fundamental factor, but it was already disclosed in the 20-F. Monitor the…
- NEUTRAL 6-KSep 11, 2026
BetterLife Pharma appointed Charles Duncan, PhD as Director and Chair of the Audit Committee…
Monitor for upcoming clinical milestones for BETR-001 (migraine/headache disorders) and any further capital raises, as the company's going-concern status and minimal cash ($12,570 as of Jan 31…
All BETRF filing & press-release reports (7)
- 6-K reportSep 30, 2026
- SC 13G reportSep 22, 2026
- 6-K reportSep 15, 2026
- 6-K reportSep 11, 2026
- 6-K reportAug 24, 2026
- 6-K reportJun 26, 2026
- 6-K reportApr 13, 2026